TrueVue an innovative monitoring system to improve patient outcomes, reduce mortality and reduce healthcare costs

点击翻译按钮获取中文摘要

Deltex Medical has been awarded an Innovate UK Smart Award to develop TrueVue - a disruptive technology for the diagnosis and management of the haemodynamics of surgical and critical care patients. It is designed for all patients from new-born to adult, anaesthetised or awake, across all hospital settings. Medicine today faces increasingly complex cases as the population ages. Protecting patients from haemodynamic errors through improved monitoring would save thousands of lives, improve outcomes and reduce costs. Diagnostic haemodynamic equipment needs to display the interaction of blood flow and pressure if it is to be truly effective.Haemodynamic instability and low blood pressure are frequent, with consequences such as myocardial infarctions, stroke and kidney injury. Complications have serious clinical and financial consequences; unplanned intensive care admissions; longer hospital stay; increased readmissions; increased 30-day mortality; and shorter patient lifespan after discharge.Monitors dependent on blood pressure measurement alone are failing to meet this need for all patients across all hospital settings. The novel TrueVue Velocity Pressure Loops system is the first monitor to display both aortic blood flow and aortic blood pressure simultaneously throughout the heartbeat. TrueVue will be a significant contribution to patient safety for surgical and critical care patients.TrueVue will operate by use of Doppler ultrasound and other non-invasive methods to measure blood flow velocity and combine this with standard measures of arterial blood pressure. The system can currently be used in all major surgical procedures and intensive care units; and with developments in non-invasive methods already foreseen by Deltex, could be applied across all surgical and after care procedures.The UK is a global clinical leader in haemodynamics and Enhanced Recovery Programmes. TrueVue is based on sound haemodynamic practices and is both a significant patient safety advance and a global business opportunity for the UK. TrueVue will address a market need in the UK alone of nearly 600,000 surgical patients, 90,000 intensive care admissions and a global market of nearly 40million in major/high-risk surgery and ICU. With expansion into all categories of surgery through non-invasive methods the technology has a potential market of 278million procedures annually.Deltex Medical expects to increase its market share, and revenues 5-fold to £35m in the first 6 years of sales.